Sanofi Signs a License Agreement with Biond for BND-22

 Sanofi Signs a License Agreement with Biond for BND-22


  • Biond to receive $125M up front in cash and will be eligible to receive ~$1B+ as development, regulatory & commercial milestones, along with royalties on sales of the therapy
  • Biond will lead P-Ia study of BND-22, assessing its safety & tolerability as a single agent and in combination with approved cancer therapies as well as exploring potential associations b/w BND-22 anti-tumor activity, select tumor and blood-based biomarkers. Sanofi will be further responsible for clinical development and commercialization of BND-22
  • BND-22 is a humanized IgG4, antagonist Ab targeting ILT2 receptor in development for solid tumors. The first P-Ia study of BND-22 is anticipated to start by mid-2021

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: 20 Minutes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post